Inflammation, immunological reaction and role of infection in pulmonary hypertension

Clinical Microbiology and Infection

Volumn 17, Issue 1, 2011, Pages 7-14

  Pullamsetti, S S ^a,b   Savai, R ^b   Janssen, W ^a   Dahal, B K ^b   Seeger, W ^a,b   Grimminger, F ^b   Ghofrani, H A ^b   Weissmann, N ^b   Schermuly, R T ^a,b  

^a MAX PLANCK INSTITUTE FOR HEART AND LUNG RESEARCH   (Germany)

^b JUSTUS LIEBIG UNIVERSITY   (Germany)

Author keywords

Immunity; Infection; Inflammation; Pulmonary hypertension; Review

Indexed keywords

CHEMOKINE RECEPTOR CCR2; FRACTALKINE; INTERLEUKIN 1; INTERLEUKIN 6; MONOCYTE CHEMOTACTIC PROTEIN 1; RANTES; STROMAL CELL DERIVED FACTOR 1ALPHA; TUMOR NECROSIS FACTOR ALPHA;

ADAPTIVE IMMUNITY; B LYMPHOCYTE; CLINICAL ASSESSMENT; CYTOTOXIC T LYMPHOCYTE; DENDRITIC CELL; HELPER CELL; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; HUMAN HERPESVIRUS 8; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNOCOMPETENT CELL; INFECTION; INFLAMMATION; INNATE IMMUNITY; MACROPHAGE; MAST CELL; MONOCYTE; PARASITOSIS; PATHOGENESIS; PREDICTION; PRIORITY JOURNAL; PROGNOSIS; PULMONARY HYPERTENSION; REGULATORY T LYMPHOCYTE; REVIEW; RISK FACTOR; SCHISTOSOMIASIS; T LYMPHOCYTE;

EID: 78650107038     PISSN: 1198743X     EISSN: 14690691     Source Type: Journal    
DOI: 10.1111/j.1469-0691.2010.03285.x     Document Type: Review

References (50)

1. Rubin LJ. Pulmonary arterial hypertension. Proc Am Thorac Soc 2006; 3: 111-115.
2. Simonneau G, Robbins IM, Beghetti M et al. Updated clinical classification of pulmonary hypertension. J Am Coll Cardiol 2009; 54: S43-S54.
3. Budhiraja R, Tuder RM, Hassoun PM. Endothelial dysfunction in pulmonary hypertension. Circulation 2004; 109: 159-165.
4. Hassoun PM, Mouthon L, Barbera JA et al. Inflammation, growth factors, and pulmonary vascular remodeling. J Am Coll Cardiol 2009; 54: S10-S19.
5. Dorfmuller P, Perros F, Balabanian K, Humbert M. Inflammation in pulmonary arterial hypertension. Eur Respir J 2003; 22: 358-363.
6. Libby P. Inflammatory mechanisms: the molecular basis of inflammation and disease. Nutr Rev 2007; 65: S140-S146.
7. Medzhitov R. Origin and physiological roles of inflammation. Nature 2008; 454: 428-435.
8. Nicolls MR, Taraseviciene- Stewart L, Rai PR, Badesch DB, Voelkel NF. Autoimmunity and pulmonary hypertension: a perspective. Eur Respir J 2005; 26: 1110-1118.
9. Davis C, Fischer J, Ley K, Sarembock IJ. The role of inflammation in vascular injury and repair. J Thromb Haemost 2003; 1: 1699-1709.
10. Perros F, Dorfmuller P, Souza R et al. Dendritic cell recruitment in lesions of human and experimental pulmonary hypertension. Eur Respir J 2007; 29: 462-468.
11. Tamby MC, Chanseaud Y, Humbert M et al. Anti- endothelial cell antibodies in idiopathic and systemic sclerosis associated pulmonary arterial hypertension. Thorax 2005; 60: 765-772.
12. Tamby MC, Humbert M, Guilpain P et al. Antibodies to fibroblasts in idiopathic and scleroderma- associated pulmonary hypertension. Eur Respir J 2006; 28: 799-807.
13. Wang W, Yan H, Zhu W et al. Impairment of monocyte- derived dendritic cells in idiopathic pulmonary arterial hypertension. J Clin Immunol 2009; 29: 705-713.
14. Heath D, Yacoub M. Lung mast cells in plexogenic pulmonary arteriopathy. J Clin Pathol 1991; 44: 1003-1006.
15. Miyata M, Sakuma F, Ito M, Ohira H, Sato Y, Kasukawa R. Athymic nude rats develop severe pulmonary hypertension following monocrotaline administration. Int Arch Allergy Immunol 2000; 121: 246-252.
16. Banasova A, Maxova H, Hampl V et al. Prevention of mast cell degranulation by disodium cromoglycate attenuates the development of hypoxic pulmonary hypertension in rats exposed to chronic hypoxia. Respiration 2008; 76: 102-107.
17. Tuder RM, Groves B, Badesch DB, Voelkel NF. Exuberant endothelial cell growth and elements of inflammation are present in plexiform lesions of pulmonary hypertension. Am J Pathol 1994; 144: 275-285.
18. Pinto RF, Higuchi Mde L, Aiello VD. Decreased numbers of T- lymphocytes and predominance of recently recruited macrophages in the walls of peripheral pulmonary arteries from 26 patients with pulmonary hypertension secondary to congenital cardiac shunts. Cardiovasc Pathol 2004; 13: 268-275.
19. Minamino T, Christou H, Hsieh CM et al. Targeted expression of heme oxygenase- 1 prevents the pulmonary inflammatory and vascular responses to hypoxia. Proc Natl Acad Sci USA 2001; 98: 8798-8803.
20. Miyata M, Sakuma F, Yoshimura A, Ishikawa H, Nishimaki T, Kasukawa R. Pulmonary hypertension in rats. 1. Role of bromodeoxyuridine- positive mononuclear cells and alveolar macrophages. Int Arch Allergy Immunol 1995; 108: 281-286.
21. Itho T, Nagaya N, Ishibashi- Ueda H et al. Increased plasma monocyte chemoattractant protein- 1 level in idiopathic pulmonary arterial hypertension. Respirology 2006; 11: 158-163.
22. Ulrich S, Taraseviciene- Stewart L, Huber LC, Speich R, Voelkel N. Peripheral blood B lymphocytes derived from patients with idiopathic pulmonary arterial hypertension express a different RNA pattern compared with healthy controls: a cross sectional study. Respir Res 2008; 9: 20.
23. Bonnet S, Rochefort G, Sutendra G et al. The nuclear factor of activated T cells in pulmonary arterial hypertension can be therapeutically targeted. Proc Natl Acad Sci USA 2007; 104: 11418-11423.
24. Austin ED, Rock MT, Mosse CA et al. T lymphocyte subset abnormalities in the blood and lung in pulmonary arterial hypertension. Respir Med 2009; 104: 454-462.
25. Taraseviciene- Stewart L, Nicolls MR, Kraskauskas D et al. Absence of T cells confers increased pulmonary arterial hypertension and vascular remodeling. Am J Respir Crit Care Med 2007; 175: 1280-1289.
26. Daley E, Emson C, Guignabert C et al. Pulmonary arterial remodeling induced by a Th2 immune response. J Exp Med 2008; 205: 361-372.
27. Ulrich S, Nicolls MR, Taraseviciene L, Speich R, Voelkel N. Increased regulatory and decreased CD8+ cytotoxic T cells in the blood of patients with idiopathic pulmonary arterial hypertension. Respiration 2008; 75: 272-280.
28. Humbert M, Monti G, Brenot F et al. Increased interleukin- 1 and interleukin- 6 serum concentrations in severe pulmonary hypertension. Am J Respir Crit Care Med 1995; 151: 1628-1631.
29. Voelkel N, Tuder R, Bridges J, Arend W. Interleukin- 1 receptor antagonist treatment reduces pulmonary hypertension generated in rats by monocrotaline. Am J Respir Cell Mol Biol 1994; 11: 664-675.
30. Steiner MK, Syrkina OL, Kolliputi N, Mark EJ, Hales CA, Waxman AB. Interleukin- 6 overexpression induces pulmonary hypertension. Circ Res 2009; 104: 236-244.
31. Fujita M, Mason R, Cool C, Shannon J, Hara N, Fagan K. Pulmonary hypertension in TNF- a- overexpressing mice is associated with decreased VEGD gene expression. J Appl Physiol 2002; 93: 2162-2170.
32. Balabanian K, Fousset A, Dorfmuller P et al. Cx(3)c chemokine fractalkine in pulmonary arterial hypertension. Am J Respir Crit Care Med 2002; 165: 1419-1425.
33. Perros F, Dorfmuller P, Souza R et al. Fractalkine- induced smooth muscle cell proliferation in pulmonary hypertension. Eur Respir J 2007; 29: 937-943.
34. Dorfmuller P, Zarka V, Durand- Gasselin I et al. Chemokine RANTES in severe pulmonary arterial hypertension. Am J Respir Crit Care Med 2002; 165: 534-539.
35. Sanchez O, Marcos E, Perros F et al. Role of endothelium- derived CC chemokine ligand 2 in idiopathic pulmonary arterial hypertension. Am J Respir Crit Care Med 2007; 176: 1041-1047.
36. Young KC, Torres E, Hatzistergos KE, Hehre D, Suguihara C, Hare JM. Inhibition of the SDF- 1/CXCR4 axis attenuates neonatal hypoxia- induced pulmonary hypertension. Circ Res 2009; 104: 1293-1301.
37. Humbert M. Mediators involved in HIV- related pulmonary arterial hypertension. AIDS 2008; 22 (suppl 3): S41-S47.
38. Cool CD, Rai PR, Yeager ME et al. Expression of human herpesvirus 8 in primary pulmonary hypertension. N Engl J Med 2003; 349: 1113-1122.
39. Henke- Gendo C, Mengel M, Hoeper MM, Alkharsah K, Schulz TF. Absence of Kaposi's sarcoma- associated herpesvirus in patients with pulmonary arterial hypertension. Am J Respir Crit Care Med 2005; 172: 1581-1585.
40. Bull TM, Meadows CA, Coldren CD et al. Human herpesvirus- 8 infection of primary pulmonary microvascular endothelial cells. Am J Respir Cell Mol Biol 2008; 39: 706-716.
41. Moorman J, Saad M, Kosseifi S, Krishnaswamy G. Hepatitis C virus and the lung: implications for therapy. Chest 2005; 128: 2882-2892.
42. Robalino BD, Moodie DS. Association between primary pulmonary hypertension and portal hypertension: analysis of its pathophysiology and clinical, laboratory and hemodynamic manifestations. J Am Coll Cardiol 1991; 17: 492-498.
43. Reiberger T, Ferlitsch A, Sieghart W et al. HIV-HCV co- infected patients with low CD4+ cell nadirs are at risk for faster fibrosis progression and portal hypertension. J Viral Hepatol 2010; 17: 400-409.
44. Butrous G, Ghofrani HA, Grimminger F. Pulmonary vascular disease in the developing world. Circulation 2008; 118: 1758-1766.
45. Crosby A, Jones FM, Southwood M et al. Pulmonary vascular remodeling correlates with lung eggs and cytokines in murine schistosomiasis. Am J Respir Crit Care Med 2010; 181: 279-288.
46. Obeyesekere I, Peiris D. Pulmonary hypertension and filariasis. Br Heart J 1974; 36: 676-681.
47. Quarck R, Nawrot T, Meyns B, Delcroix M. C- reactive protein: a new predictor of adverse outcome in pulmonary arterial hypertension. J Am Coll Cardiol 2009; 53: 1211-1218.
48. Sanchez O, Sitbon O, Jais X, Simonneau G, Humbert M. Immunosuppressive therapy in connective tissue diseases- associated pulmonary arterial hypertension. Chest 2006; 130: 182-189.
49. Gomberg- Maitland M, Olschewski H. Prostacyclin therapies for the treatment of pulmonary arterial hypertension. Eur Respir J 2008; 31: 891-901.
50. Wilkins MR, Ali O, Bradlow W et al. Simvastatin as a treatment for pulmonary hypertension trial (SIPHT). Am J Respir Crit Care Med 2010 [Epub ahead of print].